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Background: NXL104 is a novel-structure b-lactamase inhibitor with potent activity against both class
A and class C enzymes. Among the class A carbapenemases, KPC-type enzymes are now spreading
rapidly and KPC-related carbapenemase resistance is an emerging phenomenon of great clinical
importance. The activity of NXL104 against KPC b-lactamases was examined.
Methods: Enzymatic activity of puriﬁed recombinant KPC-2 was measured with nitroceﬁn as reporter
substrate and inhibition by NXL104 was measured by determination of IC50 values. Antimicrobial sus-
ceptibility testing of various b-lactams combined with a ﬁxed concentration of NXL104 at 4 mg/L
against strains producing KPC enzymes was performed by the broth microdilution method.
Results: NXL104 was a potent inhibitor of KPC-2 with an IC50 of 38 nM. NXL104 restored the antimicro-
bial activity of ceftazidime, ceftriaxone, imipenem and piperacillin against Enterobacteriaceae strains
producing KPC-2 or KPC-3. MIC values of ceftazidime against KPC producers were reduced by up to
1000-fold by combination with NXL104.
Conclusions: NXL104 inhibitory activity is unique in terms of spectrum, encompassing class A
extended-spectrum b-lactamases, class C enzymes and class A carbapenemases. Given the limited
therapeutic options available for infections caused by multiresistant Enterobacteriaceae isolates,
NXL104 b-lactamase inhibitor is a promising agent to be used in combination with a b-lactam to
protect its antibacterial activity.
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Introduction
Owing to their broad spectrum antibacterial activity and to their
stability against most common b-lactamases, carbapenems play
a major role in the treatment of severe and difﬁcult-to-treat
infections caused by Gram-negative bacteria.
1 The carbapenem
group of antibiotics is often considered as the last resort treat-
ment for nosocomial infections caused by multiresistant
Gram-negative organisms, when the other b-lactams are no
longer useful. Hence, the recent reports of resistance to carbape-
nems are of great concern.
2
Within the heterogeneous group of carbapenemases, the
Ambler class A KPC family represents a relatively recent and
emerging concern. KPC-type enzymes in carbapenem-resistant
Klebsiella pneumoniae strains were ﬁrst reported in 2001 in
North Carolina, USA
3 and until 2005 were limited to sporadic
occurrences in the eastern USA; they are now endemic in some
facilities in New York
4 and show an expanding geographic
range. Bacterial strains producing KPC enzymes have been
reported from a few patients in Europe (France and UK),
5,6
Central and South America (Colombia, Brazil and Puerto
Rico)
7–9 and China,
10 while hospital outbreaks have been
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11 and in Greece.
12 Essentially limited to iso-
lates of K. pneumoniae in initial surveillance reports, KPC
b-lactamases have since been identiﬁed in a variety of
Enterobacteriaceae species, as well as in Pseudomonas
aeruginosa.
13 The analysis of genetic structures surrounding
blaKPC genes have evidenced the presence of a novel Tn3-based
transposon, Tn4401, which is likely to be the origin of blaKPC
mobilization and further insertion into various plasmids of non--
clonally related organisms.
14 Seven KPC variants have so far
been described (KPC-2 to -8, KPC-1 being synonymous with
KPC-2).
15 This small group of enzymes displays a broad sub-
strate spectrum with high hydrolytic efﬁciency against most
clinically relevant b-lactam antibacterial agents, including the
carbapenems.
3 KPC enzymes are only poorly inhibited by mar-
keted b-lactamase inhibitors, therefore the addition of clavula-
nate, tazobactam or sulbactam generally does not rescue the
b-lactam antibacterial activity. KPC enzymes are thus character-
ized by a broad-spectrum hydrolytic activity, and high interspe-
cies and intercontinental dissemination potential.
NXL104 is a new non-b-lactam inhibitor of b-lactamases
currently in clinical development (Figure 1). It displays a broad-
spectrum inhibition proﬁle against both class A and class C
enzymes,
16 and a variable level of activity against class D
enzymes. Both types of enzyme are inactivated very efﬁciently
with low IC50 (concentration resulting in 50% inhibition) values,
low turnover numbers and form highly stable complexes.
NXL104 has virtually no intrinsic antibacterial activity, but
efﬁciently protects b-lactams from hydrolysis in a variety of
strains producing class A and class C enzymes, including
extended-spectrum b-lactamases.
17
The objective of this study was to evaluate the inhibition of
the KPC-2 enzyme by NXL104 and to determine the in vitro
antibacterial activity of various b-lactam/NXL104 combinations
against highly resistant strains producing KPC carbapenemases.
Materials and methods
Bacterial strains and MIC determination
Four bacterial strains producing KPC enzymes were isolated in
French hospitals in the Paris area between 2002 and 2005:
Escherichia coli 2138 and Enterobacter cloacae 7506
18 (Pitie ´-
Salpe ´trie `re hospital); E. cloacae MAC
19 (Tenon hospital); and
K. pneumoniae YC
5 (Kremlin-Bice ˆtre hospital). Two other KPC
producers tested were US isolates (VAKP and VA8).
MIC values were determined using the CLSI microdilution broth
methods for antimicrobial susceptibility testing with cation-adjusted
Mueller–Hinton broth.
20 Bacterial inocula were adjusted to contain
5 10
5 cfu/mL. MIC values were interpreted according to break-
points established by the CLSI guideline.
21
The following commercially available antimicrobials were used:
ceftazidime pentahydrate; piperacillin; ceftriaxone; amoxicillin; and
imipenem. The commercially available b-lactam inhibitors lithium
clavulanate and tazobactam were assessed. NXL104 was from
Novexel SA. Inhibitors were added to b-lactam antibiotics at a ﬁxed
concentration of 4 mg/L.
b-Lactamase assay
Puriﬁed KPC-2 enzyme was kindly provided by S. Petrella and
W. Sougakoff;
18 purity as assessed by SDS–PAGE was .95%. The
steady-state kinetic parameters (Km and kcat) were determined by
measuring the initial hydrolysis rates of nitroceﬁn at 485 nm on a
SOFTmax
w Pro spectrophotometer (Molecular Devices), in 50 mM
phosphate buffer (pH 7.0) containing 0.1 mg/mL BSA to prevent
enzyme denaturation. Reactions were performed in a total volume of
200 mLa t3 7 8C. Inhibition of enzyme activity was determined in
the same conditions with 100 mM nitroceﬁn as reporter substrate
and after a 5 min or a 30 min pre-incubation of 3 nM KPC-2 with
various concentrations of inhibitors. IC50s corresponded to the con-
centration of inhibitor needed to reduce the initial rate of hydrolysis
of nitroceﬁn by 50%. The kinetic parameters (Km and kcat) and
IC50s were determined by non-linear ﬁtting to the Michaelis–
Menten equation using GraFit (version 5.0) software from Erithacus
(Horley, Surrey, UK), and ﬁnal values were determined by averaging
results from at least three independent experiments.
Results and discussion
Inhibition of enzyme activity
The kcat and Km values of KPC-2 for nitroceﬁn were 59+5s
21
and 52+2 mM, respectively, in close agreement with published
values.
3 NXL104 demonstrated potent inhibition of KPC-2
activity when tested after a 5 min and a 30 min pre-incubation
step, with IC50 values of 170 and 35 nM, respectively. Reference
inhibitors were substantially less active, with IC50 values in the
micromolar range:  100 and 6.5 mM for clavulanate after 5 and
30 min of incubation, respectively; and 50 and 9.2 mM, respect-
ively, for tazobactam. Complete inhibition of KPC-2 could not
be achieved with clavulanate, even at the highest concentrations
tested;  25%–50% KPC-2 activity remained with clavulanate
in the concentration range 5–100 mM. In contrast, KPC-2
activity was abolished by NXL104 at 1 mM. Inhibitory activity
measured for clavulanate was consistent with published data.
3
Antimicrobial activity of various b-lactam/NXL104
combinations against strains producing KPC enzymes
Six different clinical isolates of Enterobacteriaceae species
(three K. pneumoniae, one E. coli and two E. cloacae strains)
known to produce a KPC enzyme were tested for their suscepti-
bility to different b-lactam antibiotics (Table 1). They were all
found to be highly resistant to the penicillins and cephalosporins
tested, since MIC values were  2048 mg/L with amoxicillin
and piperacillin, and in the range 64 to .2048 mg/L for
ceftazidime and ceftriaxone. Imipenem MICs were in the
CLSI guidelines resistant range of  16 mg/L, except for
K. pneumoniae VA8, which was susceptible to this carbapenem
(MIC of 1 mg/L).
NXL104, clavulanate or tazobactam was added to b-lactam
antibiotics at a ﬁxed concentration of 4 mg/L. Clavulanate and
tazobactam were able to afford the b-lactam antibiotics some
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Figure 1. Chemical structure of NXL104.
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327protection from hydrolysis; however, it was only for the
K. pneumoniae VA8 isolate treated with ceftazidime that these
inhibitors reversed MICs to the susceptible range. For the ﬁve
other strains producing KPC enzymes, clavulanate (when added
to amoxicillin or ceftazidime) and tazobactam (when added to
piperacillin or ceftazidime) could not lower the MIC values
below the susceptibility breakpoint. In contrast, NXL104
efﬁciently protected piperacillin, ceftazidime, ceftriaxone and
imipenem from b-lactamase disruption, the addition of NXL104
restoring the susceptibility of KPC producers to all of these anti-
biotics. In the presence of NXL104, the MIC of the antibiotic
fell by up to 1000-fold for ceftazidime and up to 65000-fold for
ceftriaxone. When combined with NXL104, amoxicillin activity
was improved but was not restored to susceptible levels. This
may reﬂect a high efﬁciency of KPCs against amoxicillin,
as KPC enzymes have been shown to exhibit high catalytic
efﬁciencies for penicillin substrates.
3
In summary, the data provided in this study show that
NXL104 is a potent inhibitor of KPC enzymes. NXL104
rescued the antibiotic activity of various b-lactam classes, exem-
pliﬁed by piperacillin, ceftazidime, ceftriaxone and imipenem
against E. coli, K. pneumoniae and E. cloacae strains producing
KPC enzymes. The addition of NXL104 resulted in a reduction
of MIC values to below susceptibility breakpoints in all six iso-
lates tested, including those exhibiting extremely high resistance
levels. Although clavulanate and tazobactam showed some
in vitro efﬁcacy against the K. pneumoniae isolate producing
KPC-3 that had retained imipenem susceptibility, both inhibitors
were inactive against the imipenem-resistant isolates.
Clinically, KPC-positive organisms tend to be highly resistant
to multiple classes of antibiotics; high-level resistance to quino-
lones, aminoglycosides and polymyxins is frequently observed
among KPC-positive K. pneumoniae.
4,22 In addition, infections
due to organisms producing KPC carbapenemases have been
associated with high mortality in affected patients.
4,23 In the
context of the limited therapeutic options to treat infections
caused by multiresistant Gram-negatives, NXL104 is a promis-
ing agent that could be used to protect b-lactam antibiotics from
hydrolysis. The combination ceftazidime/NXL104 is currently
under clinical development and has demonstrated a remarkable
tolerance proﬁle in healthy volunteers.
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